Overview
McDermott Will & Emery advised Orakl Oncology, a pioneering precision oncology company, on a EUR 11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors. This new funding will be used to accelerate the company’s growth and support the launch of two new commercial products, O-Predict and O-Validate designed to transform the landscape of oncology drug development.
This investment follows a EUR 3 million pre-seed round in October 2023 led by Speedinvest with participation from HCVC and Verve Ventures.
The McDermott team was comprised of :
- Anthony Paronneau, partner, Ludivine Rabreau, associate and Pauline Orliange, juriste
